COVID-19 mRNA vaccination was evaluated for acute myocarditis incidence and clinical outcomes in adults, though specific quantitative results were not reported in the abstract.
Observational
What is the incidence and clinical outcomes of acute myocarditis following COVID-19 mRNA vaccination in adults?
This study evaluates the incidence and clinical outcomes of acute myocarditis following COVID-19 mRNA vaccination in US adults.
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or OlderVaccination is an essential component of the public health strategy to end the COVID-19 pandemic.1-3 Recently, there have been reports of acute myocarditis following COVID-19 mRNA vaccine administration.4-6 We evaluated acute myocarditis incidence and clinical outcomes among adults following mRNA vaccination in an integrated health care system in the US.
Simone et al. (2021) conducted an observational in Acute myocarditis. COVID-19 mRNA vaccination was evaluated on Acute myocarditis incidence and clinical outcomes. COVID-19 mRNA vaccination was evaluated for acute myocarditis incidence and clinical outcomes in adults, though specific quantitative results were not reported in the abstract.